Physician profile
Emil Blanco
NPI 1134111040
$10,930.94
in general payments reported to CMS, 2019-2025
39 companies · $2,275 in 2025
The $2,275 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $323 · 2021: $833 · 2022: $1,478 · 2023: $2,166 · 2024: $2,270 · 2025: $2,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,685 · Education: $26.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,684.98 |
| Education | $26.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,231.85 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,054.57 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $787.56 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $709.46 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $669.39 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $633.98 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $617.40 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $492.54 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $358.92 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $270.88 | 2025 | Rezdiffra |
| Qol Medical, LLC | $262.88 | 2019-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $230.68 | 2022-2023 | |
| Angiodynamics, INC. | $183.36 | 2019 | |
| Lilly USA, LLC | $169.34 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $132.92 | 2019-2024 | Ocaliva |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.